Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Gemcitabine 5Cisplatin 5Oxaliplatin 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fluorouracil 4durvalumab 3Taxes 3futibatinib 2fludarabine 2Specimen Handling 2Platinum 2Paclitaxel 2Nivolumab 2Irinotecan 2Folfox protocol 2Fluorodeoxyglucose F18 2Carboplatin 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2zimberelimab 1ulixertinib 1tocilizumab 1tivozanib 1tislelizumab 1regorafenib 1pevonedistat 1pemigatinib 1pembrolizumab 1olutasidenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cholangiocarcinoma × KP 1339 × 30 days × Clear all
NCT04421820 2026-05-18

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Bold Therapeutics, Inc.

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡